Immunitybio is trading at $8.32, up 5.2% from a comparison close of $7.91 during regular trading. This is a price-action follow-up, so a separate catalyst may not be included.
🟢 Immunitybio is trading 5.2% up
Immunitybio Inc
Related News
IBRX
ImmunityBio Reports 71% Complete Response Rate in Bladder Cancer Trial
IBRX
🔴 Immunitybio is trading 5% down today amid biotech sector weakness
IBRX
🟢 Immunitybio is trading 5.65% up today after FDA expanded ANKTIVA approval for bladder cancer treatment
IBRX
IBRX Receives Expanded FDA Approval for ANKTIVA in Bladder Cancer Treatment
IBRX